Platinum-Acrdine Compounds for Selective DNA Damage and Toxicity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current platinum-based anticancer agents, such as cisplatin, exhibit severe toxicities and acquired cross-resistance, limiting their utility due to lack of tumor selectivity and high water-insolubility, necessitating the development of novel mechanistically unique agents that overcome these drawbacks.
Innovation Solution
Development of platinum-acridine compounds that cause severe DNA damage through intercalation and platination, targeting nuclear DNA and utilizing hMATE1 as a biomarker for personalized treatment approaches to enhance chemosensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If platinum-based anticancer agents are administered systemically, then they attack tumor cells and tissues, but they also attack normal cells and tissues equally without tumor selectivity, causing severe toxicities
Solution Approach 1:
The patent applies local quality by designing platinum-acridine compounds with specific molecular structures that enable selective accumulation in tumor tissues through intercalation into DNA. The acridine moiety provides localized interaction with nuclear DNA, creating a concentration gradient that favors tumor cell targeting over normal cells, thereby maintaining anticancer activity while reducing systemic toxicity to normal tissues
Solution Approach 2:
The invention uses composite materials by combining platinum coordination complexes with acridine heterocyclic compounds to create hybrid platinum-acridine agents. This composite structure integrates the DNA-binding capability of acridine with the cytotoxic mechanism of platinum, producing a synergistic effect that enhances tumor selectivity and reduces off-target toxicity compared to conventional platinum drugs alone
2Reliability
If conventional platinum drugs are used, then they exhibit antitumor activity, but they acquire cross-resistance and have low water-solubility, limiting their utility
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of conventional platinum drugs to create platinum-acridine hybrids with altered physical and chemical properties. These structural modifications improve water solubility and eliminate cross-resistance by introducing new mechanisms of DNA damage through intercalation and platination, making the agents effective against tumors that have developed resistance to traditional platinum-based therapies
3Reliability
If platinum-acridine compounds are used to cause severe DNA damage, then they achieve high cytotoxicity and overcome chemoresistance, but they require targeted delivery mechanisms to minimize toxicity
Solution Approach 1:
The patent applies the intermediary principle by using hMATE1 as a biomarker and target for personalized treatment approaches. The hMATE1 transporter serves as an intermediary that facilitates selective uptake of platinum-acridine compounds into tumor cells, enabling high cytotoxicity and chemoresistance overcoming in target cells while minimizing DNA damage-induced toxicity in non-target cells through personalized medicine strategies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Platinum-acridines demonstrate up to 1000-fold higher activity than cisplatin in DNA repair-proficient NSCLC, maintaining high cytotoxicity and overcoming chemoresistance, while minimizing toxicity through targeted DNA damage mechanisms.
Implementation Method 1
Platinum-acridines and analogs bind to DNA via a mechanism that involves intercalation and platination nucleobase nitrogen
Implementation Method 2
Platinum-acridines and analogs bind to DNA via a mechanism that involves intercalation and platination nucleobase nitrogen
Data Source
AI summary
Platinum-acridines and analogs thereof as cytotoxic agents for cancer treatment. Also provided methods of using hMATE1 (SLC47A1) as a biomarker to identify tumors that are likely to respond to the agents, and epigenetically sensitizing tumor tissue to anticancer drugs targeting this membrane transporter.